Abstract
Eniluracil (776C85, GW776) inactivatesdihydropyrimidine dehydrogenase (DPD), the principal enzyme of5-fluorouracil (5-FU) catabolism. Inactivation of DPD eliminatesa potential mechanism for tumor 5-FU resistance and permitsachievement of reliable and predictable pharmacokincticsfollowing oral 5-FU administration. Eniluracil/5-FU hasdemonstrated efficacy as monotherapy in patients with a varietyof solid tumors when given on a 5 or 28-day dosing schedule. Theprimary and dose-limiting toxicity is myelosuppresion with the5-day schedule and diarrhea with the 28-day schedule. Thefrequency of hand-foot syndrome is minimal with either schedule.Phase III pivotal registration-directed studies witheniluracil/5-FU given by the 28-day schedule are ongoing orplanned for the near future in patients with advanced colorectal,breast and pancreatic cancer.
Similar content being viewed by others
References
Baccanari DP, Davis ST, Knick VC, Spector T: Proc Natl Acad Sci 90: 11064–11068, 1993
Spector T, Cao S, Rustum YM, Harrington JA, Porter DJT: Attenuation of the antitumor acticity of 5-fluorouracil by (R)-fluoro-5,6-dihydrouracil. Canc Res 55: 123–1241, 1995
Etienne MC, Cheradame S, Fischel JL, Formento P, Dassonville I, Renee M, Schneider M, Thyss A, Demard F, Milano G: Response to fluorouracil therapy in cancer patients. The role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 13: 1663–1670, 1995
Poon MA, O'Connell MJ, Moertel CG, Weiand JS, Cullinan SA, Everson LK, Krook JE, Mailliard JA, Laurie JA, Tschetter LK, Wiesenfeld M: Biochemical Modulation of Fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7: 1407–1418, 1989
Baker SD, Khor SP, Adjei AA, Doucette M, Spector T, Donehower RC, Grochow LB, Sartorlus SE, Noe DA, Hohneker JA, Rowinsky EK: Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. J Clin Oncol 14: 3085–3096, 1996
Grem JL: 5-fluoropyrimidines. In: Chabner BA, Longo DL (eds) Cancer Chemotherapy and Biotherapy: Principles and Practice (ed 2). Lippincott Raven, Philadelphia, PA, 1996, pp 149–217
Czejka MJ, Jager W, Schuller J, Fogl U, Weiss C, Schernthaner G: Clinical pharmacokinetics of 5-fluorouracil. Clinical pharmacokinetics of 5-fluorouracil: Influence of the biomodulating agents interferon, dipyridamole, and folinic acid alone and in combination Arzneirnittel-Forschung/Drug Res 43: 387–390, 1993
Schilsky RL, Hohneker J, Ratain MJ, Janisch L, Smetzer L, Lucas VS, Khor SP, Diasio R, Van Hoff DD, Burris HA: Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer. J Clin Oncol 49: 1450–1457, 1998
Schaaf LJ, Dobbs BR, Edwards IR, Perrier DG: Nonlinear pharmacokinctic characteristics of 5-fluorouracil (5FU) in colorectal cancer patients. Eur J Clin Pharmacol 32: 411–418, 1987
Milano G, Etienne MC, Renee N, Thyss A, Schneider M, Ramaioli A, Demard: Relationship between fluorouracil systemic exposure and tumor response and patient survival. J Clin Oncol 12: 1291–1295, 1994
Baker SD, Diasio R, Lucas VS, Khor S-P, Thomas S, Sartorius S, Donehower R, Eisenherger M, Grochow L, O'Reilly S, Hohneker J, Rowinsky E: Phase I and Pharmacologic Study of Oral 5-Fluorouracil (5-FU) on a chronic 28-day schedule in combination with the Dihydropyrimidine Dehydrogenase (DPD) Inactivator 776C85 [abstract]. Proc ASCO 15: 486, 1996
Harris BE, Song R, Soong S, Diasio R: Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50: 197–201, 1990
Piedbois P, Rougier P, Buyse M, Pignon JP, Ryan L, Hansen R, Zee B, Weinerman B, Pater J, Leichman C, MacDonald J, Benedetti J, Lokich J, Fryer J, Brufman G, Isacson R, Laplanche A, Levy E: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16: 301–308, 1998
Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG: A Prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a mid-Atlantic oncology program study. J Clin Oncol 7: 425–432, 1989
McLeod HL, Ahmed FY, Johnston SJ, O'Kelly T, Binnie N, Murray GI, Van Gennip AH, Abeling NGGM, Knight S, Cassidy J: Eniluracil treatment completely inactivated dihydropyrimidine dehydrogenase activity in colorectal tumors [abstract]. Proc ASCO 18: 201a, 1999
Mani S, Beck T, Chevlen E, Hochster H, O'Rourke M, Weaver C, Bell W, MeGuirt C, Levin J, Hohneker J, Lokich J: A Phase II Open-Label Study to evaluate a 28-day regimen of oral 5-fluorouracil (5-FU) plus 776C85 for the treatment of patients with previously untreated metastatic colorectal cancer (CRC) [abstract]. Proc ASCO 17: 281a, 1998
Schilsky R, Bukowski R, Burris H, Crawford J, Hochster H, O'Rourke M, Steinfeldt H, Doucette M, Levin J, Hohneker J: A phase II study of a rive day regimen of oral 5-fluorouracil (5-FU) plus GW776 (776C85) with or without leucovorin in patients with metastatic colorectal cancer [abstract]. Proc ASCO 16: 271a, 1997
Goldberg RM, Kugler J, Sargent DJ, Malioney MR: A Phase II trial of a seven day regimen of oral 776C85 plus a five day regimen of oral 5-fluorouracil (5-FU) in untreated patients (PTS) with Metastatic Colorectal Cancer (M-CRC): A North Central Cancer Treatment Group Study [abstract]. Proc ASCO 17: 282a, 1998
Regazzoni S, Pesce G, Marini G, Cavalli F, Goldhirsch A: Low-dose continuous intravenous infusion of 5-fluorouracil for metastatic breast cancer. Ann Oncol 7: 807–813, 1996
Huan S, Pazdur R, Singhakowinta A, Samal B, Vaitkevicius VK: Low-dose continuous infusion 5-fluorouracil. Evaluation in advanced breast carcinoma. Cancer 63: 419–422, 1989
Rivera E, Chevlen E, Eckardt J, Kennedy MJ, Sawhney R, Sutton L, Frye D, Hedrick J, McGuirt C, Levin J, Hohneker J, Hortobagyi GN: A Phase II open label study to evaluate a 28-day oral regimen of 5-fluorouracil (5-FU) plus 776C85 for the treatment of patients with taxane and anthracycline resistant advanced breast cancer: Preliminary results [abstract]. Proc ASCO 17: 113a, 1998
Burns HA, Ravdin P, Guthell J, Shepard R, Rivera E, MeGuirt C, Levin J, Decker J, Hohneker J, Winer E: Eniluracil/5FU in anthracycline and taxane refractory breast cancer [abstract]. Proc ASCO 18: 405, 1999
Smith I, Johnston S, O'Brien M, Hickish T, Harris D, Barton C: High activity with eniluracil (776C85) and continuous low dose oral 5-fluorouracil (1 mg/m2 2 daily) as firstline chemotherapy in patients with advanced breast cancer: A phase II study [abstract]. Proc ASCO 18: 402, 1999
Knowling M, Browman G, Cooke A, Siu L, Seymous L, Cripps C, Matthews S, Rodgers A: phase II study of eniluracil (776C85) and oral 5-fluorouracil (5-FU) in patients with advanced squamous cell head and neck cancer (HNC) [abstract]. Proc ASCO 18: 396a, 1999
Jacobs C, Lyman G, Velez-Garels E, Sridhar KS, Knight W, Hochster H, Goodnough LT, Mortimer JE, Einhorn LH, Schacter L, Cherng H, Dalton R, Burroughs J, Rozencweig M: A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 10: 257–263, 1992
Humerickhouse RA, Dolan ME, Haraf DJ, Brockstein B, Stenson K, Kies M, Sulzen L, Ratain MJ, Vokes EE: Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer. Clin Cancer Res 5: 291–298, 1999
Wilki N, Glimelius B, Schueller J, Van Laethem JL, Figer A, Barton C, Silveira C: Promising early results of oral 5-fluorouracil plus eniluracil (776C85) in patients with advanced adenocarcinoma of the pancreas [abstract]. Ann of Oncol 9: 46, 1998
Benson AB, Mitchell E, Abramson N, Klenke B, Ritch P, Burnham J, McGuirt C, Levin J, Hohneker J: A multicenter, phase II trial of oral eniluracil plus 5-FU in patients with inoperable hepatocellular carcinoma [abstract]. Proc ASCO 18: 985, 1999
Jiang W, Lu Z, He Y, Diasio RB: Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: implication in 5-fluorouracil-based chemotherapy. Clin Cancer Res 3: 395–399, 1997
Meta-Analysis Group in Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors. J Clin Oncol 16: 3537–3541, 1998
Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS, Griffin T: Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17: 485–493, 1999
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Levin, J., Hohneker, J. Clinical Development of Eniluracil/Fluorouracil: an Oral Treatment for Patients with Solid Tumors. Invest New Drugs 18, 383–390 (2000). https://doi.org/10.1023/A:1006457617467
Issue Date:
DOI: https://doi.org/10.1023/A:1006457617467